bortezomib will increase the level or impact of flibanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Improved flibanserin adverse consequences could arise if coadministered with various weak CYP3A4 inhibitors.Significant: The drug info on this web site is supposed to become educational. It's not a substitute

Pharmacological inhibition of the ataxia telangiectasia and Rad3-connected protein serine/threonine kinase (ATR; generally known as FRAP-related protein (FRP1)) has emerged as a promising system for most cancers therapy that exploits artificial lethal interactions with proteins linked to DNA problems repair, overcomes resistance to other therapies